Understand the source comparison
Is SS-LUP-332 Worth It: Research Grade Comparison
Before committing to SS-LUP-332, researchers should compare it against peptides with overlapping mechanisms or similar research applications. The table below evaluates key factors that determine whether SS-LUP-332 is worth it relative to established alternativ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before committing to SS-LUP-332, researchers should compare it against peptides with overlapping mechanisms or similar research applications. The table below evaluates key factors that determine whether SS-LUP-332 is worth it relative to established alternatives.
- SS-LUP-332
- ERRα/γ agonist; mitochondrial biogenesis
- Moderate. Rodent endurance data published but not independently replicated
- $500–$900
- None. No Phase I trials
- Novel mechanism studies requiring AMPK-independent pathway
- Worth it for mechanistic novelty; premature for translational work
- MOTS-C
- Mitochondrial-derived peptide; AMPK activation
- Strong. Multiple independent replications, aged rodent efficacy
- $420–$660
- Phase I tolerability completed 2024
- Aging research, metabolic rescue in older models
- Worth it for age-related studies with emerging human safety data
- GW501516
- PPARδ agonist; fatty acid oxidation
- Very strong. Extensively characterized, cancer risk documented
- $180–$350
- Phase I/II completed; discontinued due to carcinogenicity
- Proof-of-concept only; not suitable for therapeutic development
- Worth it for mechanistic comparison; unacceptable risk for translation
- 5-Amino-1MQ
- NNMT inhibitor; NAD+ preservation
- Moderate. Fat loss in rodents, limited mitochondrial data
- $320–$560
- Phase I tolerability data published
- Fat metabolism and NAD+ research
- Worth it for NAD+ pathway studies; weaker for endurance phenotypes
- Metformin (control)
- AMPK activator; Complex I inhibitor
- Extremely strong. 60+ years clinical use, thousands of studies
- $15–$40
- Extensive. Approved therapeutic
- Positive control for metabolic studies
- Always worth including as comparator for any novel metabolic compound
- SS-LUP-332 occupies a narrow research niche: labs studying ERR-mediated metabolism or seeking alternatives to AMPK activation will find it valuable, but those conducting translational research should prioritize compounds with at least Phase I human data. The mechanistic novelty that makes SS-LUP-332 interesting also makes it risky. Without independent replication of the original endurance findings, you're betting your study timeline on a single lab's published results.